On the Issue of Evaluating the Effectiveness of Vaccination of Employees of Medical Organizations against COVID-19
Relevance. Active mass vaccination of the population against a new COVID-19 is being carried out on the territory of the Russian Federation, which is recognized as a priority strategy for the country's healthcare for the near and long-term periods. One of the main risk groups that are subject t...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Numikom LLC
2022-03-01
|
| Series: | Эпидемиология и вакцинопрофилактика |
| Subjects: | |
| Online Access: | https://www.epidemvac.ru/jour/article/view/1460 |
| _version_ | 1826567430475874304 |
|---|---|
| author | T A Platonova A A Golubkova M S Sklyar E A Karbovnichaya S S Smirnova |
| author_facet | T A Platonova A A Golubkova M S Sklyar E A Karbovnichaya S S Smirnova |
| author_sort | T A Platonova |
| collection | DOAJ |
| description | Relevance. Active mass vaccination of the population against a new COVID-19 is being carried out on the territory of the Russian Federation, which is recognized as a priority strategy for the country's healthcare for the near and long-term periods. One of the main risk groups that are subject to priority vaccination is medical workers. Aims. To evaluate the effectiveness of vaccination of medical organizations ' employees against COVID-19 based on the results of a 6-month prospective follow-up. Materials and methods. The observation group consisted of 356 employees of a medical organization who were vaccinated against COVID-19 with the drug «Gam-Covid-Vac» from December 2020 to April 2021. The effectiveness of vaccination of employees was evaluated by the coefficient of IgG positivity to SARS-CoV-2 by solid-phase enzyme immunoassay 3 weeks after the first administration and 3–4 weeks after the second administration of the vaccine and then 1 time per month. Employees who were revaccinated after 5–6 months. After the initial vaccination, they were examined 10–14 days after the introduction of the first component «Gam-Covid-Vac». A total of 1921 serum samples were studied. A specific T-cell immune response was determined in two study participants without seroprotection after administration of two components of the «Gam-Covid-Vac» vaccine and eight employees with the elimination of IgG antibodies 4–5 months after vaccination using ELISPOT technology. In addition, 92 blood serum samples of 32 employees from the observation group were examined for specific antibodies to adenovirus by indirect enzyme immunoassay. From December 2020 to June 2021, the study participants were subjected to dynamic clinical observation, once a week they were examined by PCR to detect SARS-CoV-2 RNA in smears from the pharynx and nose (a total of 5696 samples). Results. After the completed course of immunization, the formation of both a humoral (in 99.4% of cases) and cellular immune response (100% among the studied samples) was confirmed. In the next 6 months after vaccination, cases of coronavirus infection were registered in 4.8% of those vaccinated, including 1 person – in the first month after vaccination and 16 – 3–5 months after vaccination. In all cases, the disease occurred in the form of an acute respiratory infection of mild or moderate severity and was characterized by a shorter period of virus isolation compared to similar data on the persistence of the virus in unvaccinated patients (15 days in vaccinated compared to 22 days in unvaccinated). It was found that the presence of immunity to adenovirus infection during vaccination with the drug «Gam-Covid-Vac» did not affect the possibility of forming an immune response to COVID-19. In the group of persons re-vaccinated with the first component of «Gam-Covid-Vac» after 5–6 months. after the initial vaccination, an immune response was received during the follow-up period. Conclusion. Thus, according to the results of the study, a high immunological and epidemiological effectiveness of vaccination against COVID-19 with the drug «Gam-Covid-Vac» was established in a group of medical workers, and the effectiveness and safety of the administration of a booster dose of the vaccine after primary vaccination was also shown. |
| first_indexed | 2024-04-10T02:49:20Z |
| format | Article |
| id | doaj.art-d90dafd80d38446e971925a949413497 |
| institution | Directory Open Access Journal |
| issn | 2073-3046 2619-0494 |
| language | Russian |
| last_indexed | 2025-03-14T11:07:25Z |
| publishDate | 2022-03-01 |
| publisher | Numikom LLC |
| record_format | Article |
| series | Эпидемиология и вакцинопрофилактика |
| spelling | doaj.art-d90dafd80d38446e971925a9494134972025-03-02T10:40:34ZrusNumikom LLCЭпидемиология и вакцинопрофилактика2073-30462619-04942022-03-01211616610.31631/2073-3046-2022-21-1-61-66815On the Issue of Evaluating the Effectiveness of Vaccination of Employees of Medical Organizations against COVID-19T A Platonova0A A Golubkova1M S Sklyar2E A Karbovnichaya3S S Smirnova4European medical center «UMMC-Health»Central research Institute for epidemiology of Rospotrebnadzor; Russian Medical Academy of Continuing Professional EducationEuropean medical center «UMMC-Health»European medical center «UMMC-Health»ERIVI, FBRI SRC VB «Vector» of Rospotrebnadzor; Ural state medical UniversityRelevance. Active mass vaccination of the population against a new COVID-19 is being carried out on the territory of the Russian Federation, which is recognized as a priority strategy for the country's healthcare for the near and long-term periods. One of the main risk groups that are subject to priority vaccination is medical workers. Aims. To evaluate the effectiveness of vaccination of medical organizations ' employees against COVID-19 based on the results of a 6-month prospective follow-up. Materials and methods. The observation group consisted of 356 employees of a medical organization who were vaccinated against COVID-19 with the drug «Gam-Covid-Vac» from December 2020 to April 2021. The effectiveness of vaccination of employees was evaluated by the coefficient of IgG positivity to SARS-CoV-2 by solid-phase enzyme immunoassay 3 weeks after the first administration and 3–4 weeks after the second administration of the vaccine and then 1 time per month. Employees who were revaccinated after 5–6 months. After the initial vaccination, they were examined 10–14 days after the introduction of the first component «Gam-Covid-Vac». A total of 1921 serum samples were studied. A specific T-cell immune response was determined in two study participants without seroprotection after administration of two components of the «Gam-Covid-Vac» vaccine and eight employees with the elimination of IgG antibodies 4–5 months after vaccination using ELISPOT technology. In addition, 92 blood serum samples of 32 employees from the observation group were examined for specific antibodies to adenovirus by indirect enzyme immunoassay. From December 2020 to June 2021, the study participants were subjected to dynamic clinical observation, once a week they were examined by PCR to detect SARS-CoV-2 RNA in smears from the pharynx and nose (a total of 5696 samples). Results. After the completed course of immunization, the formation of both a humoral (in 99.4% of cases) and cellular immune response (100% among the studied samples) was confirmed. In the next 6 months after vaccination, cases of coronavirus infection were registered in 4.8% of those vaccinated, including 1 person – in the first month after vaccination and 16 – 3–5 months after vaccination. In all cases, the disease occurred in the form of an acute respiratory infection of mild or moderate severity and was characterized by a shorter period of virus isolation compared to similar data on the persistence of the virus in unvaccinated patients (15 days in vaccinated compared to 22 days in unvaccinated). It was found that the presence of immunity to adenovirus infection during vaccination with the drug «Gam-Covid-Vac» did not affect the possibility of forming an immune response to COVID-19. In the group of persons re-vaccinated with the first component of «Gam-Covid-Vac» after 5–6 months. after the initial vaccination, an immune response was received during the follow-up period. Conclusion. Thus, according to the results of the study, a high immunological and epidemiological effectiveness of vaccination against COVID-19 with the drug «Gam-Covid-Vac» was established in a group of medical workers, and the effectiveness and safety of the administration of a booster dose of the vaccine after primary vaccination was also shown.https://www.epidemvac.ru/jour/article/view/1460coronavirus infectioncovid-19vaccination«gam-covid-vac»medical workershumoral and cellular immune response |
| spellingShingle | T A Platonova A A Golubkova M S Sklyar E A Karbovnichaya S S Smirnova On the Issue of Evaluating the Effectiveness of Vaccination of Employees of Medical Organizations against COVID-19 Эпидемиология и вакцинопрофилактика coronavirus infection covid-19 vaccination «gam-covid-vac» medical workers humoral and cellular immune response |
| title | On the Issue of Evaluating the Effectiveness of Vaccination of Employees of Medical Organizations against COVID-19 |
| title_full | On the Issue of Evaluating the Effectiveness of Vaccination of Employees of Medical Organizations against COVID-19 |
| title_fullStr | On the Issue of Evaluating the Effectiveness of Vaccination of Employees of Medical Organizations against COVID-19 |
| title_full_unstemmed | On the Issue of Evaluating the Effectiveness of Vaccination of Employees of Medical Organizations against COVID-19 |
| title_short | On the Issue of Evaluating the Effectiveness of Vaccination of Employees of Medical Organizations against COVID-19 |
| title_sort | on the issue of evaluating the effectiveness of vaccination of employees of medical organizations against covid 19 |
| topic | coronavirus infection covid-19 vaccination «gam-covid-vac» medical workers humoral and cellular immune response |
| url | https://www.epidemvac.ru/jour/article/view/1460 |
| work_keys_str_mv | AT taplatonova ontheissueofevaluatingtheeffectivenessofvaccinationofemployeesofmedicalorganizationsagainstcovid19 AT aagolubkova ontheissueofevaluatingtheeffectivenessofvaccinationofemployeesofmedicalorganizationsagainstcovid19 AT mssklyar ontheissueofevaluatingtheeffectivenessofvaccinationofemployeesofmedicalorganizationsagainstcovid19 AT eakarbovnichaya ontheissueofevaluatingtheeffectivenessofvaccinationofemployeesofmedicalorganizationsagainstcovid19 AT sssmirnova ontheissueofevaluatingtheeffectivenessofvaccinationofemployeesofmedicalorganizationsagainstcovid19 |